IP Library Granted Patent US 8,278,301
Granted Patent B2
US 8,278,301 · App. 12/466,809 · Granted Oct 2, 2012

2-alkylbenzoxazole carboxamides as 5HT3 modulators

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,278,301
App. No.
12/466,809
Granted
Oct 2, 2012
Kind
B2
Abstract

Compounds of formulae I and II: are disclosed as 5-HT 3 inhibitors. Those compounds are useful in treating CINV, IBS-D and other diseases and conditions.

Claims (15)

1. A method of treating irritable bowel syndrome, emesis, or post-operative nausea or vomiting, which comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound of formula

wherein

R 1 , R 2 and R 3 are independently selected from the group consisting of hydrogen, halogen, amino, alkylamino, dialkylamino, acylamino, morpholinyl, —O-loweralkyl, hydroxy, loweralkyl, fluoroloweralkyl, —O-lowerfluoroalkyl, methylenedioxy, ethylenedioxy, alkoxy-loweralkyl and hydroxyloweralkyl;

R 4 is a residue selected from the group consisting of:

(i) a saturated nitrogen heterocycle or methyl-substituted saturated nitrogen heterocycle, in which said nitrogen is tertiary, said heterocycle containing at least one 5 or 6-membered ring; and

(ii) an imidazolylalkyl residue wherein the imidazole of said imidazolylalkyl is optionally substituted with up to three groups chosen from halogen, (C 1 -C 4 )alkyl, substituted (C 1 -C 4 )alkyl and NH 2 ; and

R 10 is selected from the group consisting of

(i) hydrogen;

(ii) (C 1 -C 10 )alkyl;

(iii) substituted (C 1 -C 10 )alkyl;

(iv) saturated C-attached heterocyclyl; and

(v) substituted, saturated C-attached heterocyclyl.

2. A method according to claim 1 wherein said disorder is irritable bowel syndrome.

3. A method according to claim 1 for treating emesis.

4. A method according to claim 1 for treating post-operative nausea or vomiting.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 7541537 PREVIOUSLY RECORDED AT REEL: 034045 FRAME: 0951. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST. Recorded Aug 14, 2018
From: ALBANY MOLECULAR RESEARCH, INC.; ALO ACQUISITION LLC; AMRI BURLINGTON, INC.; AMRI RENSSELAER, INC.; CEDARBURG PHARMACEUTICALS, INC.; OSO BIOPHARMACEUTICALS MANUFACTURING, LLC
To: BARCLAYS BANK PLC, AS THE COLLATERAL AGENT
Reel/Frame 046796/0352 →
RELEASE OF SECURITY INTEREST Recorded Aug 31, 2017
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: ALBANY MOLECULAR RESEARCH, INC.; ALO ACQUISITION LLC; AMRI BURLINGTON, INC.; AMRI RENSSELAER, INC.; CEDARBURG PHARMACEUTICALS, INC.; OSO BIOPHARMACEUTICALS MANUFACTURING, LLC; AMRI SSCI, LLC; EUTICALS INC.
Reel/Frame 043742/0085 →
SECURITY INTEREST Recorded Oct 24, 2014
From: ALBANY MOLECULAR RESEARCH, INC.; ALO ACQUISITION LLC; AMRI BURLINGTON, INC.; AMRI RENSSELAER, INC.; CEDARBURG PHARMACEUTICALS, INC.; OSO BIOPHARMACEUTICALS MANUFACTURING, LLC
To: BARCLAYS BANK PLC, AS THE COLLATERAL AGENT
Reel/Frame 034045/0951 →
RELEASE OF SECURITY INTEREST Recorded Jul 9, 2014
From: WELLS FARGO
To: ALBANY MOLECULAR RESEARCH, INC.
Reel/Frame 033283/0357 →